Abstract-Each year, the European Union's (EU) Economics of Industrial Research & Innovation (IRI) project group will publish a report entitled "R&D Scoreboard" which summarizes the world top 1,500 to 2,500 corporations (number varies from year to year) R&D investment in the previous year. In this paper, the author will extract the top 1000 corporations from this EU 2015 report, then analyze and compare the Chinese corporations' performance versus the rest of the pool. By comparing the investment in different sectors, we found that the Chinese corporations' primary R&D investment, similar to other regions, were in the construction, IT industry, transportation, and energy sectors. However, different from other regions, Chinese R&D investment in the pharmaceuticals and biotechnology is significantly less than the rest of the world. Our next step is to compare the annual profit margin with the R&D investment percentages of these Chinese corporations. The objective is to verify whether the Chinese corporations will stick to the sustainable strategy of continuously increasing in R&D investment, regardless of the short-term revenue fluctuations.
INTRODUCTION
The Economics of Industrial Research & Innovation (IRI) is a project conducted by the Directorate on Growth and Innovation, which is one of the institutes of the European Commission's joint research centers. Each year, IRI will publish an annual scoreboard report on the world"s top 1000 to 2500 corporations" R&D investment in the previous year.
The number of corporations reported increases from 500 in the first year of 2004 to 2,500 in the latest report in 2015.
In this paper, we analyzed the scoreboard published in 2015 [1] and focus on the top 1000 corporations, rather than the entire list of 2,500 corporations. The main reason was based on the fact that the total R&D investment for the top 1,000 and all 2,500 corporations are €552.7 billion and €607.2 billion respectively. By analyzing the top 1000 corporations (40% of the 2,500), we greatly reduced the number of companies, yet we still covered 91% of the total R&D investment.
Among these top 1000 corporations, , still falling behind the USA and Japan. We should also pay attention to the fact that the USA accounts for roughly 40% of the world total R&D investment and the great China area accounts for only 7% (5.16% plus 1.73%). This gap between the USA and the Chinese corporate R&D investment will be further expanded when considering the total sales and revenues. For the Chinese corporations, the calculation of the R&D investment as a percentage of their sales and revenues usually has a much larger denominator, i.e., Chinese companies normally have much higher sales and revenues, both in terms of domestic and international markets.
In TABLE III, we showed the number of companies according to the same sector classification scheme by the IRI. The information revealed by the Table confirmed 
ANALYSIS OF THE CHINESE CORPORATIONS IN THE TOP 1000 LIST
Examining the 81 Chinese corporations that achieved the top 1000 list, they can be grouped using the same sector categories and the results are presented in TABLE III. The author has some reservation on the IRI decision of placing the HUAWEI, the Chinese company with the highest R&D investment, in the financial service sector. By combining HUAWEI with the Technology sector or the Electronic sector seems to make more sense. Nevertheless, the position of this company is still in consistent with the world trend, i.e., ICT is one off the top R&D investment sector. The second group is the Construction & Materials sector, which does reflect the recent two-three decades of growth in construction, infrastructure, high-speed railroads, and national transportation network projects in China.
This high investment in R&D also enables these Chinese companies to compete in the world market such as the bidding for high-speed railroads outside China, and the construction of ports in the Indian Ocean countries, and the Panama Canal project.
Following the construction & material sector are the Technology & Hardware Equipment sector, the Automotive & Parts sector, and the Software& Computer Services sector. This order may not be completely identical to the world ranking presented in TABLE III, but they are still in consistent with the world leading pack. The main difference lies in the "Pharmaceuticals & Biotechnology" sector which has been recognized world-wide as the top R&D investment sector, while this sector in China is falling into the last few groups. According to the Chinese culture, traditional Chinese herbs are still considered as a more gentle treatment option, comparing to the western medicine. As pointed out in [2] , national culture does correlate to the R&D investment. The low investment by the Chinese companies in the "Pharmaceuticals & Biotechnology" sector maybe best explained by the Chinese culture of using traditional herbs rather than the western approach of using synthetic medicine. 
CHINESE CORPORATES SECTOR RANKING BASED ON 2014 R&D INVESTMENT (continued)
IV SUMMARY In this paper, we analyzed the EU Commission"s publication on world companies" investment in R&D. Specifically, we extract these Chinese companies that made the top 1000 list and compare them with companies outside China. Overall, those top Chinese corporations are in line with the rest of the world, with the exception of the Pharmaceuticals & Biotechnology category. Our next task is to analyze the profit margin, the percentage of R&D with respect to the total revenue over a period of time. The objective is to verify whether Chinese corporations will still endorse the idea of continuously increasing the R&D investment, regardless of the short term disruption in the world market.
